A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Trial details
- Registry ID
- NCT06990399
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as tabirafusp alfa
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKNCT06990399 | KOD | Phase 3 | Recruiting | 2027-04Estimated |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLENCT06996080 | KOD | Phase 3 | Recruiting | 2027-02Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |